Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study

Key Points

• The study aims to evaluate the post-marketing safety signals of four JAK inhibitors specifically in alopecia areata.
• Analyzed data from the FAERS database for post-marketing reports of JAK inhibitors
• Identified adverse events related to each JAK inhibitor
• Compared safety profiles across different agents
• Observed heterogeneous safety patterns for the four JAK inhibitors
• Findings indicate that class-level warnings do not capture all risks
• Support for individualized risk assessments in clinical practice